Breaking News

Edge Nigeria: Lassa Fever Death Toll Hits 40 and 86 cases reported





Lassa fever or Lassa hemorrhagic fever (LHF) is a fever caused by the Lassa virus. It is common in West Africa. One in 80 people who get Lassa fever will die. Some cases are severe and require going to a hospital. These cases have a death rate of 1 in 5. Lassa Fever was discovered in 1969 after two nurses died from the disease. It was named for the town in Nigeria where it was first diagnosed.

The Minister of Health, Professor Isaac Adewole, has revealed that over 40 deaths have been recorded since the outbreak of the deadly viral disease, Lassa Fever in Nigeria. Speaking at a press conference in Abuja today, Adewole said the viral disease which is spread by infected rodents, has spread to ten states in the last six weeks when the first case was reported in November.



“In the last six weeks Nigeria has been experiencing Lassa fever outbreak which so far has affected 10 states in the country. The states affected include Bauchi, Nasarawa, Niger, Taraba, Kano, Rivers, Edo, Plateau, Gombe and Oyo state. The total number so far reported is 86 and 40 deaths with the mortality rate of 45%. Our laboratories have confirmed 22 cases so far, indicative of a new round trip of Lassa fever outbreak,” he said.



How people get Lassa fever


Mastomys natalensis, the natural reservoir of the Lassa fever virus

Lassa fever is transmitted from rodents to humans. It is caused by direct contact with rodent droppings. It can also be transmitted by humans to other humans by their blood. Lassa fever is common in West and Central Africa (around the equator).

Lassa fever cannot be transmitted by breathing. It is not very contagious between humans. However it is much more contagious among seriously ill patients. Lassa fever is transmitted by humans through skin lesions, mucous that is exposed to the virus, or by a patient's blood. This means healthcare workers (such as doctors and nurses) need to be especially careful in treating patients, or they risk getting the virus themselves.

Symptoms of Lassa fever


In 80% of cases, the disease does not have any symptoms and does not make people ill. In the other 20% of cases it shows symptoms and becomes much more severe. About 5,000 people die from it each year.

In infected patients, the disease has an incubation period of 5 days to 3 weeks. During this time, the virus remains dormant and does not cause harm. After this time various symptoms begin to appear including:
Vomiting (with blood)
Diarrhea (with blood)
Nausea
Stomach ache
Constipation
Difficulty Swallowing
Coughing
Seizures

Diagnosis and treatment


In laboratories, there are many ways to test if a patient has Lassa fever. However, in many of the affected regions, there is no equipment to do the tests. This means sometimes people may not be correctly tested and identified with having Lassa fever.

If a patient is diagnosed with Lassa fever, then the patient will be kept away from other people, to prevent the spread of the virus. If found early, it is possible to treat Lassa fever with the medicine Ribavirin. Despite the fact the drug is relatively cheap, the medicine is still considered expensive for many people in affected regions. Patients may also require blood transfusions and rehydration.

Pregnant women in their 3rd trimester may need their baby's birth to be induced to allow them to stand a chance of survival.

Due to the use of Ribavirin, fewer people are dying from Lassa fever.

Prevention


It is not practical to control the amount of rodents in the affected states. Therefore the best way of prevention is to keep rodents out of houses and public areas to prevent people coming into contact with infected droppings. Infected patients should also be isolated to prevent the spread of the virus (by humans to other humans). In rich countries, diseases such as Lassa fever can be easily monitored by public health organisations to prevent outbreaks. Poor countries often cannot afford these services

There is a vaccine which has shown promise in primates. It has not yet been proved effective in humans.